Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16284701 | 0.79 | PTPN1 (0.45) | PTPN1MAPTNPC1ALDH1A1LMNA | |
| SCHEMBL909930 | 0.75 | PTPN1 (0.60) | PTPN1MAPTNPC1ALDH1A1LMNA | |
| SCHEMBL14383793 | 0.74 | ALDH1A1 (0.39) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL29402768 | 0.74 | ALDH1A1 (0.43) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL1173800 | 0.74 | ALDH1A1 (0.43) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL13627465 | 0.74 | TSHR (0.38) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL7543881 | 0.73 | CA12 (0.37) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL9787737 | 0.72 | PTPN1 (0.49) | PTPN1MAPTNPC1ALDH1A1LMNA | |
| SCHEMBL16284703 | 0.71 | MAPK1 (0.42) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL30391971 | 0.71 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425631-A1 | LOW VISCOSITY URETHANE (METH)ACRYLATE MONOMERS AND THEIR USE IN PRODUCTION OF TOUGH POLYMERS WITH WELL-CONTROLLED MODULUS AND STRENGTH | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425631-A1 | LOW VISCOSITY URETHANE (METH)ACRYLATE MONOMERS AND THEIR USE IN PRODUCTION OF TOUGH POLYMERS WITH WELL-CONTROLLED MODULUS AND STRENGTH | PUF60, ACR, UMPS | PTPN1 4495/4885MAPT 288/4885NPC1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.